Health Canada approves CARVYKTI, a new multiple myeloma treatment showing significant patient benefits.

Health Canada has approved CARVYKTI for treating patients with multiple myeloma who have tried one to three prior treatments. The drug is the first BCMA-targeted therapy for this stage of the disease, showing a 74% reduction in the risk of disease progression or death compared to standard treatments. This approval follows positive results from a Phase 3 study.

November 22, 2024
3 Articles

Further Reading